Clinical Trials List
2019-02-01 - 2026-11-30
Phase III
Recruiting8
ICD-10C56.1
Malignant neoplasm of right ovary
ICD-10C56.2
Malignant neoplasm of left ovary
ICD-10C56.9
Malignant neoplasm of unspecified ovary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9183.0
Malignant neoplasm of ovary
xxxxxx
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yi-Jen Chen Division of Obstetrics & Gynecology
- 沈書慧 Division of Obstetrics & Gynecology
- Chi-Mu Chuang Division of Obstetrics & Gynecology
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- 吳華席 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Huei-Jean Huang Division of Obstetrics & Gynecology
- Ting-Chang Chang Division of Obstetrics & Gynecology
- Gigin Lin Division of Radiology
- 陳威君 Division of Obstetrics & Gynecology
- 黃彥綾 Division of Radiology
- 周宏學 Division of Obstetrics & Gynecology
- 邱健泰 Division of Obstetrics & Gynecology
- Cheng-Tao Lin Division of Obstetrics & Gynecology
- 黃寬仁 Division of Obstetrics & Gynecology
- 容世明 Division of Others -
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Cheng-Yang Chou Division of Obstetrics & Gynecology
- 鄭雅敏 Division of Obstetrics & Gynecology
- Meng-Ru Shen Division of Obstetrics & Gynecology
- Keng-Fu Hsu Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 童寶玲 Division of Obstetrics & Gynecology
- - - Division of Obstetrics & Gynecology
- 郭冠廷 Division of Others
- 陳宇立 Division of Obstetrics & Gynecology
- 施怡倫 Division of Radiology
- YING-CHENG CHIANG Division of Obstetrics & Gynecology
- 陳祈安 Division of Obstetrics & Gynecology
- 戴依柔 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Chun Chang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4- fluorophenyl)methyl]phthalazin-1(2H)-one
Dosage Form
116
Dosage
100 mg
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
69 participants
-
Global
1284 participants
